Top Markets
#1 Bedrock Bedrock +50.85%
#2 pippin pippin +21.68%
#3 IQ IQ +20.70%
#4 Naoris Protocol Naoris Protocol +17.39%
#5 Irys Irys +16.18%
#6 Magma Finance Magma Finance +15.58%
#7 ETHGas ETHGas +15.36%
#8 Aria.AI Aria.AI +15.19%
#9 パンチ (Punch) パンチ (Punch) +14.59%
#10 Bitway Bitway +12.30%
Coin of the day
Bedrock Bedrock
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Classificação em ações #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Preço da ação
$0.16328419
Valor de mercado
$204.14K
Variação (1 dia)
4.35%
Variação (1 ano)
102.45%
País
GB
Negociar Fusion Antibodies plc (FAB)

Categoria

Healthcare
Receita da Fusion Antibodies plc (FAB)
Receita em Sep 2025 TTM: $2.15M
De acordo com os últimos relatórios financeiros da Fusion Antibodies plc, a receita atual da empresa (TTM) é $2.15M. Em 2024, a empresa obteve uma receita de $1.43M uma diminuição em relação a a receita do ano 2023, que foi de $3.58M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Fusion Antibodies plc de 2013 a 2026
Receita no final de cada ano
Ano Receita Alterar
2026 (TTM) $2.15M -15.49%
2025 $2.54M 77.00%
2024 $1.43M -59.95%
2023 $3.58M -43.24%
2022 $6.31M 9.89%
2021 $5.74M 18.80%
2020 $4.83M 70.09%
2019 $2.84M -24.66%
2018 $3.77M 57.07%
2017 $2.40M 12.81%
2016 $2.13M 57.86%
2015 $1.35M 11.90%
2014 $1.20M 95.78%
2013 $615.46K 0.00%
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B 2,257,473.65%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B 560,997.32%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 668,407.67%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 423,215.14%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B 255,843.08%
NL